Back to Search
JAMES L. ABBRUZZESE M.D.
M.D.
Medical Oncology Physician
NPI: 1134233224Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
G9938(TX)
Research & Publications (20)
Activator protein-1 has an essential role in pancreatic cancer cells and is regulated by a novel Akt-mediated mechanism.
PMID 19435822·Mol Cancer Res·2009
8-other
The convergence of cancer prevention and therapy in early-phase clinical drug development.
PMID 15488755·Cancer Cell·2004
6-review
Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality.
PMID 12577227·Semin Oncol·2002
6-review
New applications of gemcitabine and future directions in the management of pancreatic cancer.
PMID 12209675·Cancer·2002
6-review
DNA repair gene polymorphisms and risk of pancreatic cancer.
PMID 19147782·Clin Cancer Res·2009
8-other
Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.
PMID 19276344·Cancer Res·2009
8-other
Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells.
PMID 19029954·Oncogene·2009
8-other
Proteasome-mediated degradation and functions of hematopoietic progenitor kinase 1 in pancreatic cancer.
PMID 19141650·Cancer Res·2009
8-other
Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer.
PMID 19237629·J Clin Oncol·2009
8-other
Highlights of the 2008 San Antonio Breast Cancer Symposium.
PMID 19274039·Clin Adv Hematol Oncol·2009
8-other
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336).
PMID 18941712·Invest New Drugs·2009
3-trial
Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation.
PMID 19020940·Ann Surg Oncol·2009
3-trial
The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States.
PMID 19070394·J Hepatol·2009
8-other
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.
PMID 19139433·J Clin Oncol·2009
3-trial
Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
PMID 19164203·J Clin Oncol·2009
3-trial
Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma.
PMID 19194760·Ann Surg Oncol·2009
8-other
Hidden biases in an observational study of bevacizumab beyond progression.
PMID 19255299·J Clin Oncol·2009
8-other
Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression.
PMID 19258429·Mol Cancer Ther·2009
7-preclinical
Antidiabetic therapies affect risk of pancreatic cancer.
PMID 19375425·Gastroenterology·2009
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1515 HOLCOMBE BLVD, 77030-4009
HOUSTON, TX 77030 - Phone
- (713) 792-6161
Quick Facts
- NPI
- 1134233224
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile